Brief: Vericel Q3 EPS USD -0.02
07/11/2024 12:55
Nov 07 (Reuters) - Vericel Q3 adjusted EBITDA margin 17%. * Q3 adjusted EBITDA USD 10 million vs. IBES estimate USD 7.53 million * Q3 net income USD -900 thousand * Q3 gross margin 72% * outlook FY revenue USD 238-242 million
Recent news on Vericel
See all newsMedTech growth concerns likely to overshadow Q3 results, Leerink says
Vericel Corp reports results for the quarter ended June 30 - Earnings Summary
Vericel beats Q2 revenue estimates, boosts annual outlook
Brief: Vericel Q2 EPS USD 0.04
Vericel beats Q1 revenue on MACI, burn care growth, lifts 2026 sales outlook